In Brooklyn, a bodega named Mr. Green is openly selling retatrutide, an experimental weight-loss drug not approved by the FDA, despite federal laws prohibiting its commercial sale. The store displays a sign advertising peptides, including retatrutide, for “weight management,” but with a disclaimer stating they are “not for human consumption.” CBS News reporters purchased a vial for $95 without any age verification or prescription. This sale highlights how the demand for retatrutide has moved from online platforms to physical stores, raising concerns among medical experts about the legality and safety of such practices. The product, labeled by Indr Labs, is marketed as “for research use only,” yet it is being sold over the counter. This situation underscores the challenges of regulating experimental drugs and the potential risks to public health.
QUESTION: How might the unregulated sale of experimental drugs like retatrutide impact public trust in medical treatments and regulatory bodies?
What a Brooklyn bodega reveals about the craze for an experimental weight-loss drug
